Genomics:
Pharmaceutical Investment, Integration and Partnerships assesses the value of
genomics to pharmaceutical companies and the most cost-effective way in which
this value can be realized in improved R&D pipelines.
Based on case studies of leading and emerging genomics companies and their
pharmaceutical partners, this report identifies best practice in genomics
alliances. The report further forecasts how the increasing maturity of the
genomics industry will change the balance of power in favor of genomics
providers, highlighting the need for an innovative approach by pharmaceutical
companies to gain access to this vital technology
View Cart
